Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: Requirement for mTORC1 activity associates with ER-alpha expression

Ben A. Hall, Tae Yeon Kim, Maxwell N. Skor, Suzanne D. Conzen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Mammalian target of rapamycin (mTOR) is an attractive target for cancer treatment. While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer,mTORinhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERα+) compared to ERα negative (ERα-) tumors. Recently, serum-and glucocorticoid-regulated kinase 1 (SGK1) was identified as a substrate of mTOR kinase activity. Previous studies have alternatively suggested that either mTORC1 or mTORC2 is exclusively required for SGK1's Ser422 phosphorylation and activation in breast cancer cells. We investigated the effect of rapamycin on the growth of several ERα+ and ERα-breast cancer cell lines and examined differences in the phosphorylation of mTOR substrates (SGK1, p70S6K, and Akt) that might account for the differing sensitivity of these cell lines to rapamycin. We also examined which mTOR complex contributes to SGK1-Ser422 phosphorylation in ERα+ versus ERα-breast cell lines. We then assessed whether inhibiting SGK1 activity added to rapamycin-mediated cell growth inhibition by either using the SGK1 inhibitor GSK650394A or expressing an SGK1 shRNA. We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERα+ MCF-7 and T47D cells, but not in ERα-MDA-MB-231 or MCF10AMyc cells. In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin. Finally, we found that rapamycin-sensitive SGK1-Ser422 phosphorylation required ERα expression in MCF-7 derived cell lines. Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERα-breast cancer.

Original languageEnglish (US)
Pages (from-to)469-479
Number of pages11
JournalBreast Cancer Research and Treatment
Volume135
Issue number2
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Sirolimus
Breast Neoplasms
Phosphorylation
Cell Line
MCF-7 Cells
mechanistic target of rapamycin complex 1
serum-glucocorticoid regulated kinase
Small Interfering RNA
Growth
70-kDa Ribosomal Protein S6 Kinases
Estrogen Receptor alpha
Neoplasms
Breast
Phosphotransferases
Cell Proliferation
Insulin

Keywords

  • Breast cancer
  • Estrogen receptor alpha (ERα)
  • Mammalian target of rapamycin (mTOR)
  • Phosphoinositide 3-kinase (PI3K)
  • Rapamycin
  • Serum and glucocorticoidregulated kinase 1 (SGK1)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer : Requirement for mTORC1 activity associates with ER-alpha expression. / Hall, Ben A.; Kim, Tae Yeon; Skor, Maxwell N.; Conzen, Suzanne D.

In: Breast Cancer Research and Treatment, Vol. 135, No. 2, 01.09.2012, p. 469-479.

Research output: Contribution to journalArticle

@article{5443f2f74254403c91b4fcff2bc0441d,
title = "Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: Requirement for mTORC1 activity associates with ER-alpha expression",
abstract = "Mammalian target of rapamycin (mTOR) is an attractive target for cancer treatment. While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer,mTORinhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERα+) compared to ERα negative (ERα-) tumors. Recently, serum-and glucocorticoid-regulated kinase 1 (SGK1) was identified as a substrate of mTOR kinase activity. Previous studies have alternatively suggested that either mTORC1 or mTORC2 is exclusively required for SGK1's Ser422 phosphorylation and activation in breast cancer cells. We investigated the effect of rapamycin on the growth of several ERα+ and ERα-breast cancer cell lines and examined differences in the phosphorylation of mTOR substrates (SGK1, p70S6K, and Akt) that might account for the differing sensitivity of these cell lines to rapamycin. We also examined which mTOR complex contributes to SGK1-Ser422 phosphorylation in ERα+ versus ERα-breast cell lines. We then assessed whether inhibiting SGK1 activity added to rapamycin-mediated cell growth inhibition by either using the SGK1 inhibitor GSK650394A or expressing an SGK1 shRNA. We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERα+ MCF-7 and T47D cells, but not in ERα-MDA-MB-231 or MCF10AMyc cells. In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin. Finally, we found that rapamycin-sensitive SGK1-Ser422 phosphorylation required ERα expression in MCF-7 derived cell lines. Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERα-breast cancer.",
keywords = "Breast cancer, Estrogen receptor alpha (ERα), Mammalian target of rapamycin (mTOR), Phosphoinositide 3-kinase (PI3K), Rapamycin, Serum and glucocorticoidregulated kinase 1 (SGK1)",
author = "Hall, {Ben A.} and Kim, {Tae Yeon} and Skor, {Maxwell N.} and Conzen, {Suzanne D.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s10549-012-2161-y",
language = "English (US)",
volume = "135",
pages = "469--479",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer

T2 - Requirement for mTORC1 activity associates with ER-alpha expression

AU - Hall, Ben A.

AU - Kim, Tae Yeon

AU - Skor, Maxwell N.

AU - Conzen, Suzanne D.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Mammalian target of rapamycin (mTOR) is an attractive target for cancer treatment. While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer,mTORinhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERα+) compared to ERα negative (ERα-) tumors. Recently, serum-and glucocorticoid-regulated kinase 1 (SGK1) was identified as a substrate of mTOR kinase activity. Previous studies have alternatively suggested that either mTORC1 or mTORC2 is exclusively required for SGK1's Ser422 phosphorylation and activation in breast cancer cells. We investigated the effect of rapamycin on the growth of several ERα+ and ERα-breast cancer cell lines and examined differences in the phosphorylation of mTOR substrates (SGK1, p70S6K, and Akt) that might account for the differing sensitivity of these cell lines to rapamycin. We also examined which mTOR complex contributes to SGK1-Ser422 phosphorylation in ERα+ versus ERα-breast cell lines. We then assessed whether inhibiting SGK1 activity added to rapamycin-mediated cell growth inhibition by either using the SGK1 inhibitor GSK650394A or expressing an SGK1 shRNA. We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERα+ MCF-7 and T47D cells, but not in ERα-MDA-MB-231 or MCF10AMyc cells. In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin. Finally, we found that rapamycin-sensitive SGK1-Ser422 phosphorylation required ERα expression in MCF-7 derived cell lines. Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERα-breast cancer.

AB - Mammalian target of rapamycin (mTOR) is an attractive target for cancer treatment. While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer,mTORinhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERα+) compared to ERα negative (ERα-) tumors. Recently, serum-and glucocorticoid-regulated kinase 1 (SGK1) was identified as a substrate of mTOR kinase activity. Previous studies have alternatively suggested that either mTORC1 or mTORC2 is exclusively required for SGK1's Ser422 phosphorylation and activation in breast cancer cells. We investigated the effect of rapamycin on the growth of several ERα+ and ERα-breast cancer cell lines and examined differences in the phosphorylation of mTOR substrates (SGK1, p70S6K, and Akt) that might account for the differing sensitivity of these cell lines to rapamycin. We also examined which mTOR complex contributes to SGK1-Ser422 phosphorylation in ERα+ versus ERα-breast cell lines. We then assessed whether inhibiting SGK1 activity added to rapamycin-mediated cell growth inhibition by either using the SGK1 inhibitor GSK650394A or expressing an SGK1 shRNA. We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERα+ MCF-7 and T47D cells, but not in ERα-MDA-MB-231 or MCF10AMyc cells. In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin. Finally, we found that rapamycin-sensitive SGK1-Ser422 phosphorylation required ERα expression in MCF-7 derived cell lines. Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERα-breast cancer.

KW - Breast cancer

KW - Estrogen receptor alpha (ERα)

KW - Mammalian target of rapamycin (mTOR)

KW - Phosphoinositide 3-kinase (PI3K)

KW - Rapamycin

KW - Serum and glucocorticoidregulated kinase 1 (SGK1)

UR - http://www.scopus.com/inward/record.url?scp=84866540757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866540757&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2161-y

DO - 10.1007/s10549-012-2161-y

M3 - Article

C2 - 22842983

AN - SCOPUS:84866540757

VL - 135

SP - 469

EP - 479

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -